- Home
- PAI vs QNCX Comparison
PAI vs QNCX Comparison
Compare PAI & QNCX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAI | QNCX |
|---|---|---|
| Founded | 1973 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 118.3M | 139.2M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | PAI | QNCX |
|---|---|---|
| Price | $12.36 | $4.44 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.75 |
| AVG Volume (30 Days) | 25.0K | ★ 1.1M |
| Earning Date | 01-01-0001 | 11-12-2025 |
| Dividend Yield | ★ 4.78% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.59 | $0.72 |
| 52 Week High | $12.63 | $4.46 |
Technical Indicators
Market Signals| Indicator | PAI | QNCX |
|---|---|---|
| Relative Strength Index (RSI) | 39.97 | 81.05 |
| Support Level | $12.36 | $3.74 |
| Resistance Level | $12.44 | $4.30 |
| Average True Range (ATR) | 0.08 | 0.46 |
| MACD | 0.01 | 0.11 |
| Stochastic Oscillator | 19.05 | 93.91 |
Price Performance
Historical ComparisonAbout PAI Western Asset Investment Grade Income Fund Inc.
Western Asset Investment Grade Income Fund Inc is a closed-end diversified investment company. The company designed as a long-term investment and not as a trading vehicle. The fund seeks a high level of current income, consistent with prudent investment risk, through investment in a diversified portfolio of debt securities. Its portfolio is invested in securities which may be convertible into or exchangeable for, or carry warrants to purchase, common stock or other equity interests; and preferred stock.
About QNCX Quince Therapeutics Inc.
Quince Therapeutics Inc is preclinical stage biopharmaceutical company focused on advancing precision therapeutics for debilitating and rare diseases. The company discovered a broad bone-targeting drug platform designed to precisely deliver small molecules, peptides, or large molecules directly to the site of bone fracture and disease to promote rapid healing with fewer off-target safety concerns compared to non-targeted therapeutics. Company pipeline includes Ataxia-Telangiectasia(EryDex), Duchenne Muscular Dystrophy, New Indications and Program Expansion Potential.